Zogenix (NASDAQ: ZGNX) is a private, specialty pharmaceutical company focused on the development and commercialization of medicines in neurology and pain. The company's portfolio includes sumatriptan DosePro - a needle-free, single-use, easy-to-use subcutaneous delivery system for sumatriptan and a late-stage controlled release opioid product utilizing the Elan SODAS technology.
Zogenix has filed 94 patents.
Serotonin receptor agonists, Substituted amphetamines, Stimulants, Designer drugs, Combination drugs
Serotonin receptor agonists, Substituted amphetamines, Stimulants, Designer drugs, Combination drugs
Latest Zogenix News
Nov 7, 2023
Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America) Publication Month : Nov 2023 Market Insights and Analyst View: Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management. The increasing elderly population has increased the prevalence of neurological condition, including epilepsy, along with increasing product launches in the market. The surge in government initiatives to increase awareness among large population and its treatment is likely to amplify the epilepsy drugs market growth in the coming years. Growth Drivers: Increasing Prevalence of Epilepsy Propels Epilepsy Drugs Market Growth Epilepsy is a neurological disorder characterized by recurrent seizures. According to the data published by the World Health Organization in February 2023, epilepsy accounts for a significant share of the global disease burden, affecting nearly 50 million people across the world. The projected proportion of the general population with active epilepsy (i.e., with the need for treatment or continuing seizures) at a given time is between 4 and 10 per 1,000 individuals. According to the same source (World Health Organization in February 2023), 5 million people are diagnosed with epilepsy every year worldwide. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. In low- and middle-income countries, this number can be as high as 139 per 100,000 individuals. This is likely due to the high risk of endemic conditions such as neurocysticercosis or malaria, birth-related injuries, and a high incidence of road traffic injuries. About 80% of individuals with epilepsy live in low- and middle-income countries. The data also reports that seizures can be controlled, and about 70% of individuals living with epilepsy could become seizure-free with appropriate use of antiseizure medicines. Antiepileptic drug therapy is the primary treatment for most patients with epilepsy. Seizure classification is a crucial element in designing the treatment plan, as some antiepileptic drugs have different effects against various seizure types. Thus, the rising prevalence and incidence of epilepsy worldwide are contributing to elevate the demand for epilepsy drugs. However, product recalls can adversely affect a company’s performance, reduce brand equity, cause panic among consumers, damage its reputation, result in revenue and market share losses, and cause an extensive amount of product returns. In recent years, there have been many product recalls in the epilepsy drugs market, negatively affecting the market growth. Below mentioned are a few recent recalls: In July 2023, Sanofi UK recalled a few batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection of traces of tiapride in the source material of vigabatrin. Sabril (vigabatrin) is used as a monotherapy for the treatment of infantile spasms (West's syndrome) and as an adjuvant for focal seizures with or without subsequent generalization that is not well controlled with other antiepileptics (under professional supervision). In July 2023, Sun Pharmaceutical Industries Inc. recalled nearly 9,000 bottles of tiagabine hydrochloride tablets for failing to meet impurity specifications during testing, according to the US Food and Drug Administration (US FDA) Enforcement Report. In November 2021, Sagent Pharmaceuticals, Inc. announced the voluntary recall of four lots of Levetiracetam Injection, USP, nationwide to the user level. Reserve sample vials found a lack of container closure integrity, which may result in a non-sterile product. In January 2020, Taro Pharmaceuticals USA, Inc. issued a voluntary nationwide recall of Lamotrigine tablets USP, 100 mg, 100 count bottles, on February 20, 2020. This single lot was found to have been cross-contaminated with a small amount of another drug (Enalapril Maleate) used to manufacture other different products at the same manufacturing facility. Lamotrigine 100 mg tablets are prescribed for epilepsy and bipolar disorder. According to the US FDA’s Recall Information updated on July 21, 2023, Aurobindo Pharma recalled 48 bottles each of 200 g and 400 g Rufinamide tablets. The recall was voluntary. Rufinamide is used to control seizures in individuals who have Lennox-Gastaut syndrome, which is a severe form of epilepsy. Thus, the increased number of recent product recalls hinders the epilepsy drugs market growth. Customize Research To Suit Your Requirement We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making. Market Size Value by Growth rate Forecast Period Have a question? Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any. Report Segmentation and Scope: The “Epilepsy Drugs Market” is segmented on the basis of treatment, distribution channel, and geography. The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics segment is estimated to register the fastest CAGR during 2022–2030. Based on distribution channel, the epilepsy drugs market is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacy segment held the largest market share, and the retail pharmacy segment is estimated to register the fastest CAGR during 2022–2030. Download Free Sample Request discounts available for Start-Ups & Universities Segmental Analysis: The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022–2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer. Epilepsy Drugs Market, by Treatment – 2022 and 2030 Request discounts available for Start-Ups & Universities Based on distribution channel, the epilepsy drugs market is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022–2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drugs market. Regional Analysis – Epilepsy Drugs Market: Based on geography, the epilepsy drugs market is segmented into five key regions: North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the epilepsy drugs market. Asia Pacific is expected to register the highest CAGR in the global epilepsy drugs market during 2022–2030. The Asia Pacific epilepsy drugs market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the epilepsy drugs market in this region is widely driven by the increasing prevalence of epilepsy along with surge in government initiatives to increase among large population in developing economies. China is expected to hold the major market share and India is expected to anticipate the highest CAGR. In 2019, the prevalence of epilepsy in India ranged from 3 to 12 per 1,000 people, with a significant number of incidences reported in the rural population. Due to substantial gaps in knowledge and practice, a majority of people with epilepsy in India do not receive suitable treatment, leading to a treatment gap. About one-third of people with epilepsy have drug-resistant epilepsy. According to a study, epilepsy is common in patients aged 30–50 years with male preponderance. Focal epilepsy was more prevalent in India. Levetiracetam and valproate are the most prescribed AEDs for focal and generalized epilepsy, respectively. Moreover, drug development is propelling the growth of the epilepsy drug market in the country. For instance, in March 2021, Alkem Laboratories announced the launch of Brivasure, an affordable antiepileptic drug for the treatment of epilepsy in India, post-patent expiry of innovator product of Brivaracetam on February 21, 2021. Brivasure has been approved by the Drugs Controller General of India (DCGI). The drug has exhibited a faster onset of action efficacy with a favorable safety profile. Thus, owing to the aforementioned factors, the epilepsy drugs market is likely to grow efficiently. China being the most populated country in the world is one with the most patients with neurological disorders. According to the Centers of Disease Control and Prevention, the prevalence rate of active epilepsy in China is 0.48% to 8.5%; there are approximately 9 million people with epilepsy in Mainland China, two-thirds of whom are children. ~30% of patients with epilepsy are not capable of controlling their seizures with the AEDs that are currently available in the market; thus, this disease has significant unmet medical needs. Moreover, the drug approvals in the country are propelling the market growth. For instance, in August 2021, Eisai Co., Ltd. obtained two additional approvals of the antiepileptic drug (AED) Fycompa, as “a monotherapy for partial-onset seizures” and “an adjunctive treatment / a monotherapy for a pediatric indication for partial onset seizures in patients with epilepsy four years of age and older” in China from the National Medical Products Administration. Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. Through this approval, Fycompa is now available in China as a monotherapy and an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy four years of age and older. The growth of the epilepsy drug market in China is primarily attributed to rising cases of epilepsy and increasing developments by the market players to develop epilepsy drugs. Industry Developments – Epilepsy Drugs Market: Various initiatives taken by leading players operating in the epilepsy drugs market are listed below: In October 2023, Novartis completed the Sandoz's spin-off through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts. Each holder received one Sandoz share for every five Novartis shares held at the close of business on October 3, 2023. The separation of Sandoz has led Novartis to complete its transformation, allowing it to focus as a medicines company. In September 2023, Sanofi sold Pharmanovia, a firm established in the UK, 11 brands from its portfolio related to the central nervous system, including the epilepsy medications Gardenal and Frisium. Along with Tercian, which treats anxiety and psychotic problems in patients who have already failed other medications, Sanofi is also getting rid of the epilepsy medication Gardenal and the nausea and vertigo medication Stemetil. In January 2023, Pfizer Inc expanded its commitment to An Accord for a Healthier World. An Accord for a Healthier World is an initiative launched in May 2022 to reduce health inequities existing between many lower-income countries and the rest of the world. Pfizer Inc will offer its complete product portfolio of medicines and vaccines for 1.2 billion people living in 45 lower-income countries. In January 2023, Catalyst Pharmaceuticals Inc acquired the US rights for FYCOMPA (perampanel) CIII from Eisai Co., Ltd (Eisai). The acquisition has allowed Catalyst Pharmaceuticals Inc to have an increased US commercial presence in neurology. It has also helped in the expansion of the product portfolio with an established, first-in-class, commercial-stage epilepsy asset. In January 2022, UCB acquired Zogenix for US$ 1.9 billion in a bid to bolster its epilepsy portfolio by adding Fintepla (fenfluramine), a marketed drug for the treatment of seizures associated with Dravet syndrome, a rare form of childhood epilepsy. Competitive Landscape and Key Companies - Epilepsy Drugs Market: UCB SA, Novartis AG, Pfizer Inc, GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma company, Teva Pharmaceutical Industries Ltd, Catalyst Pharmaceuticals Inc, and Alkem Laboratories Ltd are among the prominent companies operating in the epilepsy drugs market. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide. Report Coverage Alkem Laboratories Ltd The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review. Data Collection and Secondary Research: As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain. Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends. Primary Research: The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team. For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise. A typical research interview fulfils the following functions: Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook Validates and strengthens in-house secondary research findings Develops the analysis team’s expertise and market understanding Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to: Industry participants: VPs, business development managers, market intelligence managers and national sales managers Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry. Below is the breakup of our primary respondents by company, designation, and region: Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection. Data Analysis: Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level. 3.1 Macro-Economic Factor Analysis: We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities. 3.2 Country Level Data: Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential. 3.3 Company Profile: The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size. 3.4 Developing Base Number: Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis. Data Triangulation and Final Review: The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization. We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports. We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time. Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out. Submit
Zogenix Frequently Asked Questions (FAQ)
When was Zogenix founded?
Zogenix was founded in 2006.
Where is Zogenix's headquarters?
Zogenix's headquarters is located at 12671 High Bluff Drive, San Diego.
What is Zogenix's latest funding round?
Zogenix's latest funding round is Acq - P2P.
How much did Zogenix raise?
Zogenix raised a total of $199M.
Who are the investors of Zogenix?
Investors of Zogenix include UCB, Scale Venture Partners, Clarus, Domain Associates, Life Science Angels and 7 more.
Who are Zogenix's competitors?
Competitors of Zogenix include Zyla Life Sciences, Charleston Laboratories, Intarcia Therapeutics, Afferent Pharmaceuticals, Combinent BioMedical Systems and 7 more.
Compare Zogenix to Competitors
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.
Naryx Pharma is focused on development of its product candidates of inhaled, nebulized, intranasal drug formulations.
Orexo is a pharmaceutical company that focuses on the development of improved pharmaceuticals. The company's main offerings include innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Orexo primarily sells to the healthcare industry. It is based in Uppsala, Sweden.
Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.
Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).